BioNTech's BNT324 aims to outpace rivals in cancer treatment with its unique bispecific antibody design. Read more here.

Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent ...

We recently compiled a list of the 12 Best Growth Stocks to Buy and Hold for the Long Term. In this article, we are going to ...

Join us for a quick overview of BioNTech SE, a Biotechnology company whose shares moved 0.3% today. Here are some facts about the stock that should help you see the bigger picture: BioNTech SE has ...

When the smoke cleared, BioNTech's shares closed the day more than 6% lower. The Food and Drug Administration (FDA), a ...

Q1 2025 Earnings Call Transcript May 5, 2025 Operator: Welcome to BioNTech’s First Quarter 2025 Earnings Call. I would like ...

In late April, Summit Therapeutics revealed interim OS data from HARMONi-2 for its PD-1/VEGF bispecific antibody, ivonescimab ...

German drugmaker BioNTech reported Monday wider net loss in its first quarter with weak revenues. Further, the company ...

Rocketing to a price of $106.75 during today's morning trading session, shares of BioNTech SE are still -23.88% below their average target price of $140.24. Could there be more upside potential for ...

The leader in the Covid-19 mRNA vaccine, BioNTech, is now looking at expanding the potential of mRNA technology. This starts with vaccines, with candidates for shingles, tuberculosis, malaria, HIV, ...

Pfizer Inc. and BioNTech SE failed to knock out any of Alnylam Pharmaceuticals Inc.’s patents in a case over the partners’ Covid-19 vaccines, as a federal judge said he made no findings that would let ...

December 13, 2024 US FDA lifts partial clinical hold on BioNTech cancer drug study BioNTech SE said on Friday it has been informed by its partner OncoC4 that the U.S. Food and Drug Administration ...